Amlacher R, Baumgart J, Härtl A, Weber H, Kühnel H J, Schulze W, Hoffmann H
Central Institute of Microbiology and Experimental Therapy, Academy of Sciences of the GDR, Jena.
Arch Geschwulstforsch. 1990;60(1):11-8.
The influence of age of experimental animals on the antileukemic activity, toxicity and distribution of ambazone, a new potential antineoplastic agent, was studied in 2- and 12-month-old B6D2F1 mice. The predominant effect observed was a significant reduction of the antileukemic action of this compound in old-aged mice. Together with a slight increase in several toxicity parameters this caused a marked reduction of the therapeutic index in 12-month-old mice compared to younger individuals. Furthermore, a general tendency to increased ambazone levels in liver, kidneys and thymus of old-aged mice was observed. Our data therefore provide further evidence that age has to be taken into consideration as one factor that may account for the variety of drug response frequently observed during clinical therapy with anticancer agents.
在2月龄和12月龄的B6D2F1小鼠中研究了实验动物年龄对一种新的潜在抗肿瘤药物氨巴腙的抗白血病活性、毒性及分布的影响。观察到的主要效应是该化合物在老年小鼠中的抗白血病作用显著降低。与几个毒性参数略有增加一起,这导致12月龄小鼠的治疗指数与年轻个体相比显著降低。此外,观察到老年小鼠肝脏、肾脏和胸腺中氨巴腙水平有普遍升高的趋势。因此,我们的数据提供了进一步的证据,表明年龄必须作为一个因素加以考虑,该因素可能解释在抗癌药物临床治疗期间经常观察到的药物反应差异。